[(18)F]2-fluoro-2-deoxy-D-glucose PET/CT in mediastinal masses.
Computed tomography (CT) and magnetic resonance imaging (MRI) are excellent modalities for the localization of mediastinal masses and there are often features that may allow the correct diagnosis to be made. However, CT and MRI cannot usually assess the aggressiveness of masses or identify viable tumour in residual masses after chemotherapy. Metabolic imaging using [(18)F]fluorodeoxyglucose (FDG)-positron emission tomography/CT, although not required in many cases, may be helpful for further characterization of masses and to guide the most appropriate site for biopsy.
Rankin
S
S
Department of Radiology, Guy's Hospital, St Thomas Street, London, UK. sheila.rankin@gstt.nhs.uk
D019788:Fluorodeoxyglucose F18; D006801:Humans; D008479:Mediastinal Neoplasms / Q000000981:diagnostic imaging*; D009373:Neoplasms, Germ Cell and Embryonal / Q000000981:diagnostic imaging; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D013945:Thymoma / Q000000981:diagnostic imaging; D013953:Thymus Neoplasms / Q000000981:diagnostic imaging
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18